期刊文献+

卵巢癌腹水非细胞成分对肿瘤的影响 被引量:3

Effect of acellular fraction of ovarian cancer ascites on tumor
原文传递
导出
摘要 卵巢癌病死率居妇科肿瘤最高,早期诊断率低,多数初次诊断时即为晚期。超过1/3的卵巢癌以及几乎全部的复发患者伴有腹水的产生。卵巢癌腹水中非细胞成分丰富复杂,包括细胞因子、蛋白质、代谢物和外泌体,形成复杂的腹水肿瘤微环境,影响肿瘤细胞的生物学行为及疾病进展。现就卵巢癌腹水非产细胞成分的种类、对肿瘤细胞及疾病的影响作一概述。 Ovarian cancer has the highest mortality among gynecologic cancers. The rate of early diagnosis is low and most cases have reached an advanced stage at the initial diagnosis. More than one-third of ovarian cancer patients present a large amount of ascites at the time of diagnosis. Acellular fraction of ovarian cancer ascites richly includes cytokines, proteins, metabolites, and exosomes, constitutes a unique and complicated tumor microenvironment, and influences the biological behavior of tumor cells and the progression of the disease. This paper gives an overview of the acellular fraction of ovarian cancer ascites and its effect on tumor.
作者 王霞 郝晓莹 赵卫红 郝敏 Wang Xia;Hao Xiaoying;Zhao Weihong;Hao Min(Department of Gynecology and Obstetrics,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处 《中华临床医师杂志(电子版)》 CAS 2018年第3期168-172,共5页 Chinese Journal of Clinicians(Electronic Edition)
关键词 卵巢癌 腹水 非细胞成分 Ovarian cancer Ascites Acellular fraction
  • 相关文献

参考文献11

二级参考文献168

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2郑亚峰.紫杉醇脂质体联合卡铂与传统紫杉醇联合卡铂治疗晚期卵巢癌的疗效及毒副作用比较[J].柳州医学,2010(3):63-65. 被引量:12
  • 3Amalinei C, Caruntu ID, Giusca SE, et al. Matrix metalloproteinases involvement in pathologic conditions [ J ]. Rom J Morphol Embryol, 2010,51 (2) :215 -228.
  • 4Gershtein ES, Kushlinsky DN, Levkina NV, et al. Relationship be- tween the expression of VEGF signal components and matrix metal- loproteinases in ovarian tumors [ J ]. Bull Exp Biol Med, 2011,151 (4) :449 -453.
  • 5Hu J, Chen C, Su Y, et al. Vascular endothelial growth factor pro- motes the expression of cyclooxygenase 2 and matrix metalloprotein- ases in Lewis lung carcinoma ceils [ J ~. Exp Ther Med ,2012,4 (6) : 1045 - 1050.
  • 6Zhuo W,Chen Y, Song X, et al. Endostatin specifically targets both tumor blood vessels and lymphatic vessels [ J ]. Front Med, 2011,5 (4) :336 -340.
  • 7Passot G, Dupre A. Intraperitoneal bevacizumab combined with cy- toreductive surgery : a pre - clinical study of tolerance and pharmaco- kinetics in an animal model [ J 1. Clinical and Translational Ontolo- gy,2012,14(12) :931 -936.
  • 8Kinoshita J, Fushida S, Makino I, et al. The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports [ J ]. Gan To Kagaku Ryoho, 2011,38 ( 12 ) : 2360 - 2362.
  • 9Kobold S, Hegewisch-Becker S, Oechsle K, et al. Intraperitoneal VEGF inhibition using bevaeizumab: a potential approach for the symptomatic treatment of malignant aseites[ J]. Oncologist,2009,14 (12) : 1242 - 1251.
  • 10Suzuki Y, Saeki T, Aogi K, et al. A multicenter phase II study of TSU-68 ,a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane [ J ]. Int J Clin On- col ,2012,15 : 1385.

共引文献107

同被引文献27

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部